Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Treatment of antiretroviral-drug-resistant HIV-1 infection.

Deeks SG.

Lancet. 2003 Dec 13;362(9400):2002-11. Review.

PMID:
14683662
2.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
3.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
4.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for Treatment of HIV.

Ann Intern Med. 2002 Sep 3;137(5 Pt 2):381-433.

PMID:
12617573
6.

Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.

[No authors listed]

Prescrire Int. 2004 Aug;13(72):144-50.

PMID:
15532140
7.

It is time to consider third-line options in antiretroviral-experienced paediatric patients?

Zyl GU, Rabie H, Nuttall JJ, Cotton MF.

J Int AIDS Soc. 2011 Nov 15;14:55. doi: 10.1186/1758-2652-14-55.

8.

Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.

Prosperi MC, Zazzi M, Punzi G, Monno L, Colao G, Corsi P, Di Giambenedetto S, Meini G, Ghisetti V, Bonora S, Pecorari M, Gismondo MR, Bagnarelli P, Carli T, De Luca A; ARCA Collaborative Group.

J Med Virol. 2010 Dec;82(12):1996-2003. doi: 10.1002/jmv.21927.

PMID:
20981785
9.

Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097).

Delaugerre C, Peytavin G, Dominguez S, Marcelin AG, Duvivier C, Gourlain K, Amellal B, Legrand M, Raffi F, Costagliola D, Katlama C, Calvez V.

J Med Virol. 2005 Nov;77(3):345-50.

PMID:
16173015
10.

Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.

Piketty C, Race E, Castiel P, Belec L, Peytavin G, Si-Mohamed A, Gonzalez-Canali G, Weiss L, Clavel F, Kazatchkine MD.

AIDS. 1999 Jul 30;13(11):F71-7.

PMID:
10449277
11.

Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy.

Pulido F, Arribas JR, Hill A, Van Delft Y, Moecklinghoff C.

Antivir Ther. 2011;16(1):59-65. doi: 10.3851/IMP1710.

PMID:
21311109
12.

Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.

Landman R, Capitant C, Descamps D, Chazallon C, Peytavin G, Katlama C, Pialoux G, Bentata M, Brun-Vézinet F, Aboulker JP, Yéni P; ANRS 127 Study Group.

J Antimicrob Chemother. 2009 Jul;64(1):118-25. doi: 10.1093/jac/dkp146. Epub 2009 May 6.

PMID:
19420019
13.

Treatment with lopinavir/ritonavir in heavily pretreated subjects failing multiple antiretroviral regimens in clinical practice.

Romano L, Peduzzi C, Venturi G, Di Pietro M, Carli T, Corsi P, Gonnelli A, Valensin PE, Zazzi M.

J Acquir Immune Defic Syndr. 2002 Aug 15;30(5):533-5. No abstract available.

PMID:
12154345
14.

Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients.

Youle M.

J Antimicrob Chemother. 2007 Dec;60(6):1195-205. Epub 2007 Sep 21. Review.

PMID:
17890281
15.

Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088).

Vray M, Meynard JL, Dalban C, Morand-Joubert L, Clavel F, Brun-Vézinet F, Peytavin G, Costagliola D, Girard PM; Narval Trial Group.

Antivir Ther. 2003 Oct;8(5):427-34.

PMID:
14640390
16.

Genotypic resistance tests for the clinical management of patients with primary HIV infection.

Narciso P, Lazzarin A.

Scand J Infect Dis Suppl. 2003;106:66-70. Review.

PMID:
15000588
17.

Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen.

Stürmer M, Dauer B, Moesch M, Haberl A, Mueller A, Locher L, Knecht G, Hanke N, Doerr HW, Staszewski S.

Antivir Ther. 2007;12(1):25-30.

PMID:
17503744
18.

No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients.

Ghosn J, Wirden M, Ktorza N, Peytavin G, Aït-Mohand H, Schneider L, Dominguez S, Bricaire F, Calvez V, Costagliola D, Katlama C.

AIDS. 2005 Oct 14;19(15):1643-7.

PMID:
16184034
19.

Characterization of HIV-1 from patients with virological failure to a boosted protease inhibitor regimen.

Lillemark MR, Gerstoft J, Obel N, Kronborg G, Pedersen C, Jørgensen LB, Madsen TV, Katzenstein TL.

J Med Virol. 2011 Mar;83(3):377-83. doi: 10.1002/jmv.21997.

PMID:
21264856
20.

Successful rescue therapy with darunabir (TMC114) in HIV-infected patients who have failed several ritonavir-boosted protease inhibitors.

Poveda E, Blanco F, García-Gascó P, Alcolea A, Briz V, Soriano V.

AIDS. 2006 Jul 13;20(11):1558-60.

PMID:
16847414

Supplemental Content

Support Center